GlassScriptPhysician profile
Paul Montany
NPI 1750377099
$10,963.52
in general payments reported to CMS, 2019-2025
17 companies · $2.95 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.20 · 2020: $718 · 2021: $3,828 · 2022: $103 · 2023: $5,815 · 2024: $398 · 2025: $2.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Travel and Lodging: $1,916 · Food and Beverage: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Travel and Lodging | $1,915.52 |
| Food and Beverage | $300.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,559.54 | 2021-2025 | Da Vinci Surgical System, Davinci Xi |
| Stryker Corporation | $1,057.89 | 2020-2024 | 1788 |
| Abbvie INC. | $55.72 | 2023-2024 | |
| Allergan, INC. | $54.79 | 2022 | |
| Novo Nordisk INC | $47.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.38 | 2019 | |
| Pulmonx Corporation | $21.14 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.72 | 2021 | |
| Astellas Pharma US INC | $15.04 | 2021 | |
| Lilly USA, LLC | $14.71 | 2019 | |
| Mylan Specialty L.P. | $14.57 | 2020 | |
| Avanir Pharmaceuticals, INC. | $14.50 | 2019 | |
| Grifols USA, LLC | $13.38 | 2021 | |
| Vifor Pharma, INC. | $13.27 | 2019 | |
| Baudax Bio INC. | $12.45 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12.30 | 2020 | |
| Opko Pharmaceuticals, LLC | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Montany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.